Workshops will offer a chance to review the latest treatment data and health care policies, examine their implications for our patients, and strengthen the skills needed to improve the quality of services.

Monday, April 23, 2012
10:30 a.m. – 12:00 p.m.

A1 Methadone Maintenance 101

A2 Beyond Mars – The Training Institute at Albert Einstein College of Medicine

A3 How to Prepare Your OTP for Healthcare Reform: Things you can do!

A4 Beyond the MOTHER Study: Clinical Implications of Treating Pregnant Patients

A5 Implementing Electronic Health Records, Achieving Meaningful Use

Monday, April 23, 2012
1:30 p.m. – 3:00 p.m.

#1 Project ECHO: A Model for Expanding Community-Based Access to Treatment

#2 Genetics Matters! Research that Impacts Future Opioid Dependence Treatment

#3 Integrated Care Partners Project: An Integrated, Recovery-focused Care Model for People with Mixed Opioid, Medical and Mental Disabilities

Monday, April 23, 2012
4:00 p.m. – 5:30 p.m.

B1 Treatment Planning M.A.T.R.S.

B2 Is it Possible to Treat the Psychopathology of Heroin Addicts Only with Assisted Outpatient Treatment – (EUROPAD)

B3 Addressing Resistance to Medication Assisted Treatment

B4 Patient Care Coordination and Medication Reconciliation

B5 Creating an LGBT Safe Space: Inclusivity Improvement Treatment Outcomes

Monday, April 23, 2012
6:30 p.m. – 8:00 p.m.

Digital Access to Medication (D-ATM) Town Hall: Using Technology in Opioid Treatment to Prepare for Disasters & Prevent Service Discontinuity

Tuesday, April 24, 2012
10:30 a.m. – 12:00 p.m.

C1 Meeting the Needs of Patients with Co-Occurring Disorders

C2 Engaging Families in the Recovery Process

C3 Methadone 201

C4 Patient Activation: Empowering the Patient’s Full Participation in Their Recovery

C5 Utilizing Prescription Monitoring Programs to Enhance Medication Monitoring

Tuesday, April 24, 2012
1:30 p.m. – 3:00 p.m.

D1 Therapeutic Partnerships: The Most Important Evidence-Based Practice

D2 Improving Efficiency and Cost through Patient-Directed Recovery-Oriented Care

D3 Emergency Management & Planning in OTPs

D4 Electronic Information System Implementation at an Opioid Treatment Program

D5 The Overdose Prevention Toolkit for Opioid Treatment Programs

Wednesday,  April 25, 2012
8:00 a.m. – 9:30 a.m.

E1 Recovery Partnerships: Developing and Integrating Peer Mentoring within MAT

E2 Integrating Evidence-Based Therapies for Co-Occurring Disorders

E3 Methadone from Las Vegas & Tel Aviv to Macao, from Minneapolis to Vietnam

E4 Delivering Successful MAT Services to Persons with Chronic Pain

E5 Mindfulness Based Stress Reduction: A Means for Reducing Substance Abuse

Wednesday, April 25, 2012
9:45 a.m. – 11:15 a.m.

F1 New Issues in the Diagnosis and Treatment of HCV

F2 Medication Assisted Treatment Implementation in Community Correctional Environments (MATICCE): Preliminary Findings

F3 Sharing Our Future: Updates and Opportunities for the Addiction Care Field

F4 Comprehensive Treatment of the Pregnant Substance User

A1 Methadone Maintenance 101

Monday, April 23, 2012
10:30 a.m. – 12:00 p.m.

Lesley Dickson, MD, Center for Behavioral Health, Las Vegas, NV

Methadone maintenance treatment has been available for decades; yet many clinicians do not understand how and why it is effective in treating opioid dependence and addiction. The presenter will review the basic elements of opioid agonist treatment; examine the pharmacologic aspects of methadone; present initial screening, admission procedures, and assessment techniques; describe associated medical conditions associated with opioid dependence and addiction; evaluate the efficacy of methadone therapy; and review other opioid agonist treatments.

A2 Beyond MARS—The Training Institute at Albert Einstein College of Medicine
Monday, April 23, 2012     10:30 a.m. – 12:00 p.m.

Moderator: Ira J. Marion, MA, Albert Einstein College of Medicine, Bronx, NY

Presenters:

Sarah Church, PhD, Albert Einstein College of Medicine,Division of Substance Abuse, Bronx, NY

Suzanne Hall-Westcott, MS, Beyond MARS, The MARS Training Institute at Albert Einstein College of Medicine, Bronx, NY

Walter Ginter, CMA, Medication Assisted Recovery Support Project, National Alliance for Medication Assisted (NAMA) Recovery, Bronx, NY

The effectiveness of Peer Recovery Support Services for substance use dependence has been established and is evidence-based. The MARS (Medication Assisted Recovery Support) Peer Recovery Support Services (PRSS) Project is the only national demonstration project targeted specifically to patients in Opioid Treatment Programs. The Beyond MARS Training Institute has recently been established to provide PRSS training for OTPs throughout the nation to replicate the success of the MARS project. The workshop presenters will recruit six new OTPs who wish to have peers/patients and staff trained to replicate the success of the MARS Project, at no cost to the OTPs.

A3 How to Prepare Your OTP for Healthcare Reform: Things you can do!
Monday, April 23, 2012
10:30 a.m. – 12:00 p.m.

Abigail Kay, MD, Thomas Jefferson University, Philadelphia, PA

Laura Murray, MD, Northwest Human Services, Philadelphia, PA

Trusandra Taylor, MD, JEVS Human Services, Philadelphia, PA

Healthcare Reform and the transformation of the American healthcare delivery system is impacting OTPs in many ways. Learn how to integrate medication assisted treatment with mainstream healthcare. This workshop will present lessons learned and practical strategies to establish relationships with federally qualified health centers (FQHCs), patient-centered medical homes (PCMH)/ healthcare homes, and to improve integration and best practice coordination of care for co-occurring psychiatric disorders. A central theme and essential element of the role of electronic health records (EHRs) with the interface of healthcare reform and opioid treatment programs will be reviewed. Each presenter will provide practical resources for providers.

A4 Beyond the MOTHER Study: Clinical Implications of Treating Pregnant Patients
Monday, April 23, 2012
10:30 a.m. – 12:00 p.m.

Karol Kaltenbach, PhD, Jefferson Medical College, Philadelphia, PA

John McCarthy, MD, Bi-Valley Medical Clinic, Carmichael, CA

Lauren Jansson, MD, Johns Hopkins University School of Medicine, Baltimore, MD

The MOTHER study demonstrated the relative safety and efficacy of buprenorphine compared to methadone within the parameters of a rigorous research protocol involving in-patient induction, fetal monitoring, and transitional use of morphine that may be impractical in routine clinical practice. This presentation will include a discussion of the complex issues in developing practical guidelines for the use of buprenorphine in pregnancy; a discussion of an Intrauterine Abstinence Syndrome (IAS) that might occur during maternal opioid withdrawal, complicating either buprenorphine inductions or methadone tapers; and a discussion of results from a study investigating fetal neurobehavioral effects in methadone vs. buprenorphine exposed pregnancies.

A5 Implementing Electronic Health Records, Achieving Meaningful Use
Monday, April 23, 2012
10:30 a.m. – 12:00 p.m.

Nicholas Reuter, MPH, Substance Abuse and Mental Health Services Administration, Rockville, MD

Belinda Greenfield, PhD, NYS OASAS, Bureau of Treatment, New York, NY

Lisa Cook, ACSW, Ku Aloha Ola Mau, Honolulu, HI

Both the American Recovery and Reinvestment Act and the Affordable Care Act are driving health systems toward the use of information technology, including electronic health records (EHR) for service delivery, quality improvement, cost containment, and increased patient control and financial challenges that affect how OTPs adopt health information technology and develop interoperable systems. Providers and facilities, including OTPs, can be eligible for incentive payments where they demonstrate “meaningful use” of certified EHR technology.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).

#1 Project ECHO: A Model for Expanding Community-Based Access to Treatment
Monday, April 23, 2012
1:30 p.m. – 3:00 p.m.

Miriam Komaromy, MD, University of New Mexico School of Medicine, Albuquerque, NM

Sanjeev Arora, MD, University of New Mexico Health Sciences Center, Albuquerque, NM

Project Extension for Community Healthcare Outcomes (ECHO), developed at the University of New Mexico, improves access to best practice care for complex health problems such as hepatitis C for underserved populations. Using state-of-the-art multipoint video conferencing technology, best practice protocols, and case based learning, ECHO trains and supports primary care providers to develop knowledge and self-efficacy to deliver complex disease care. This workshop will describe the ECHO model and summarize its success with treating hepatitis C, explain how the ECHO model can be used to treat addiction, and share how the model for treating addictions and HCV can be replicated.

#2 Genetics Matters! Research that Impacts Future Opioid Dependence Treatment
Monday, April 23, 2012
1:30 p.m. – 3:00 p.m.

Elizabeth Ducat, NP, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY

Mary Jeanne Kreek, MD, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY

Brenda Ray, NP, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY

This workshop will discuss recent findings from ongoing genetics research performed at Rockefeller University and/or in collaboration with several MMTs located in New York City, Las Vegas, and Tel Aviv, Israel. Presenters will describe the functional effects of mu-opioid receptor variant A118G in healthy subjects and its potential relevance for future addiction treatment; the association of specific genetic variants with methadone dose required for effective treatment of opioid dependence; and the effect of ethnicity, gender and drug use history on obtaining informed consent for genetics addiction research and the importance of treatment providers in the research process.

#3 Integrated Care Partners Project: An Integrated, Recovery-focused Care Model for People with Mixed Opioid, Medical, and Mental Disabilities

Monday, April 23, 2012
1:30 p.m. – 3:00 p.m.

Alan Mathis, MS, Liberation Programs, Bridgeport/Norwalk, CT

David Stayner, PhD, Yale Program for Recovery and Community

Health, Yale School of Medicine, New Haven, CT

The workshop presents first-year findings and lessons learned from the Integrated Care Partners (ICP) pilot project. This multidisciplinary project serves 60 people with co-occurring addictions, medical, and mental health problems—patients who have previously “fallen through the cracks” between traditionally siloed services, without lasting engagement.

Presenters will describe the integrated, recovery-focused engagement/treatment model employed, findings from structured patient interviews, and other clinical/treatment findings. They will also present lessons learned while building an effective service provision partnership between agencies with divergent treatment specialties and cultures, including challenges and opportunities found in creative dialogue between patient, professional and peer staff, and agency leadership.

B1 Treatment Planning M.A.T.R.S.
Monday, April 23, 2012
4:00 p.m. – 5:30 p.m.

Mark E. Disselkoen, LCSW, Center for the Application fo rSubstance Abuse Technology at the University of Nevada, Reno, NV

James Von Busch, LPC, Center for the Application for Substance Abuse Technology at the University of Nevada, Reno, NV

The National Institute on Drug Abuse (NIDA) and the Substance Abuse Mental Health Services Administration (SAMHSA) Blending Team developed this course. For this course, the concepts of assessment and treatment planning were “blended” to demonstrate the importance of using a standardized assessment tool when treatment planning. Participants will be introduced to the Addiction Severity Index (ASI) and the electronic version, called the DENS. Highlighted are the basics of treatment planning and case file documentation. Time will be given during the course for participants to practice new treatment planning skills. No previous training in ASI is required.

B2 Is it Possible to Treat the Psychopathology of Heroin Addicts Only with Assisted Outpatient Treatment—(EUROPAD)

Monday, April 23, 2012
4:00 p.m. – 5:30 p.m.

Pier Paolo Pani, MD, Public Health Department, Cagliari, Italy

Icro Maremmani, MD, University of Pisa, Vincent P. Dole Dual

Diagnosis Unit, ‘Santa Chiara’ University Hospital, Pisa, Italy

Angelo G.I. Maremmani, MD, ‘Santa Chiara’ University Hospital, Pisa Italy

This EUROPAD-sponsored workshop focuses on the prominent psychopathology of heroin addicts and treatment using methadone or buprenorphine. There is recent research evidence that supports an antipsychotic, anxiolitic, antipanic, and mood stabilizing effect of opioid medications. The presenters will discuss three questions:

1.) Does the prominent psychopathology of heroin addicts exist?

2.) What is the specific psychopathology of heroin addicts at treatment entry?

3.) Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?

B3 Addressing Resistance to Medication Assisted Treatment

Monday, April 23, 2012
4:00 p.m. – 5:30 p.m.

Olivia Ryan, MPA, National Office ATTC, Kansas City, MO

Thomas E. Freese, PhD, Pacific Southwest ATTC, Los Angeles, CA

Laurie J. Krom, MS, National Office ATTC, Kansas City, MO

This presentation will address efforts by the ATTC Network to decrease the gap between research and practice and to influence understanding of factors that enhance uptake of innovations. This presentation outlines how pairing research with innovative dissemination techniques can enhance the use of EBPs related to MAT. The presentation will provide an overview of the Buprenorphine Suite, a training product designed by the ATTC Network to provide the SUD treatment field with the tools to access and adopt NIDA treatment protocols. Additionally this presentation will identify research undertaken by the Network which identifies barriers to providing MAT to minority populations.

B4 Patient Care Coordination and Medication Reconciliation
Monday, April 23, 2012
4:00 p.m. – 5:30 p.m.

Marie A. Hardy, CASAC, Beth Israel Medical Center, OTP, New York, NY

Darnell Watson, BA, Beth Israel Medical Center, OTP, New York, NY

Adina Trotman, PA, Beth Israel Medical Center, OTP, New York, NY

Reconciliation of medications taken by a patient in OTP is a critical safety issue. It is crucial for OTP clinics to assure coordination of care among providers, to assure effective methadone medication doses and thoroughly evaluate any contraindicated medication issues. The presenters will describe the scope of problems for one OTP in which 30% of patients are receiving prescriptions for psychotropic and pain medications; address the approach to managing coordination of care and medication reconciliation; and discuss the inter-disciplinary approach to evaluate all medications, coordination of care, and patient education. Examples of evaluations and consents will be provided.

B5 Creating an LGBT Safe Space: Inclusivity Improves Treatment Outcomes

Monday, April 23, 2012
4:00 p.m. – 5:30 p.m.

Edward G. Johnson, LPC, Southeast Addiction Technology Transfer Center, Charleston, SC

Lesbian, Gay, Bisexual or Transgender (LGBT) individuals enter treatment programs with a unique set of challenges. Unaddressed, these issues all too often contribute to unsuccessful treatment outcomes. This didactic and experiential workshop will review the general constructs of sexual orientation and gender identity. It will explore the particular issues and life experiences of this frequently hidden minority that have contributed to the development of substance use disorders. Participants will become familiar with interventions specific to the LGBT individuals phase of identity development and will be introduced to ways of creating supportive, affirming and inclusive treatment environments.

6:30 p.m.–8:00 p.m.

Digital Access to Medication (D-ATM) Town Hall: Using Technology in Opioid Treatment to Prepare for Disasters & Prevent Service Discontinuity

Arlene Stanton, PhD, Substance Abuse and Mental Health

Services Administration (SAMHSA), Rockville, MD

LT Brandon Johnson, MBA, Substance Abuse and Mental Health

Services Administration (SAMHSA), Rockville, MD

Daksha Arora, PhD, Westat, Rockville, MD

SAMHSA’s D-ATM project (“Digital Access to Medication”) was conceived as a technological approach to help ensure OTPs can effectively and safely provide medication to patients who have been displaced from opioid treatment programs (OTPs) where they are normally enrolled. D-ATM was developed in the wake of the attacks of 9-11 and then Katrina, but over time, has evolved as an important tool to support continuity of treatment at OTPs even when dealing with more routine service discontinuities.

As AATOD 2012 convenes, D-ATM will be in its fourth year of the current phase, which has focused on beginning implementation into OTPs across the country. This Town Hall will provide an overview and status report on D-ATM, including recent explorations into enlarging the universe of D-ATM clinics by linking with State systems. Participants will also discuss ‘lessons learned’ with setting up and using the D-ATM system and dealing with real-life disasters in the last few years.

Representatives of SAMHSA and other Federal and State agencies, members of the D-ATM Steering Committee (including representatives of AATOD, NAMA Recovery, COMPA, SOTAs, and others), and program directors, patients and staff who have had experience in working with D-ATM or in dealing with disasters, large or small, are especially encouraged to attend.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).

C1 Meeting the Needs of Patients with Co-Occurring Disorders

Tuesday, April 24, 2012
10:30 a.m. – 12:00 p.m.

Joan E. Zweben, PhD, University of California, San Francisco, CA

This workshop will discuss how counselors can help integratethe treatment of psychiatric disorders into the opioid treatment program. We will discuss addictive behavior and psychiatric problems, barriers to addressing them, prioritization of treatment tasks and appropriate education for patients. We will focus on anxiety disorders (especially PTSD) and mood disorders, and also review screening and assessment of suicide risk from the perspective of agency protocols as well as the role of the counselor. Treatment issues will include psychosocial issues (coping strategies, stigma), medication issues (attitudes, feelings, adherence), and collaboration with physicians.

C2 Engaging Families in the Recovery Process

Tuesday, April 24, 2012
10:30 a.m. – 12:00 p.m.

John Hamilton, LMFT, Recovery Network of Programs, Bridgeport, CT

Donna Rivera, LADC, Recovery Network of Programs, Bridgeport, CT

Karen Reekie, CAC, Recovery Network of Programs, Bridgeport, CT

Family therapy has been recognized as a highly effective treatment modality in the addiction field for many years yet it has not been widely adopted for the treatment of opioid dependence. This workshop will identify some of the benefits as well as challenges in implementing family involvement in the recovery process and will identify concrete strategies on how to improve your family programs at your agencies. The presenters will describe the process of successful implementation of family involvement in a community treatment agency in Bridgeport, Connecticut and how it significantly improved patient satisfaction and treatment outcomes.

C3 Methadone 201

Tuesday, April 24, 2012
10:30 a.m. – 12:00 p.m.

Laura McNicholas, MD, Philadelphia VAMC, Philadelphia, PA

Susan Neshin, MD, JSAS Healthcare, Inc., Neptune, NJ

Trusandra Taylor, MD, JEVS Human Services, Philadelphia, PA

This interactive workshop is designed for the physician and clinician who have already taken Opioid Maintenance Pharmacotherapy: A Course for Clinicians and is now treating patients in an opioid treatment program involving methadone maintenance. The intent of this workshop is to provide an opportunity for formal instruction as well as sharing of information among participants. Presentations include an update on methadone treatment in the pregnant dependent patient with answers to frequently asked questions and a discussion of the use and abuse of benzodiazepines in the methadone-maintained patient. There will be time for open discussion.

C4 Patient Activation: Empowering the Patient’s Full Participation in their Recovery

Tuesday, April 24, 2012
10:30 a.m. – 12:00 p.m.

Suzan Swanton, LCSW-C, Substance Abuse and Mental Health

Services Administration (SAMHSA), Rockville, MD

Shannon Taitt, MPA, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

The need to incorporate meaningful mechanisms for patients to actively collaborate in their health care is a re-occurring theme in quality health care movements as well as in recovery-oriented systems of care for substance use conditions. Patient activation is a process that emphasizes the patient’s role as an active, equal and meaningful member of the treatment team. Following an overview of SAMHSA’s Recovery Support Services Initiative, this workshop will focus on the knowledge, skills and attitudes needed to embrace patient activation as a critical part of care, and programmatic issues to consider when adopting this innovation into clinical services.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).

C5 Utilizing Prescription Monitoring Programs to Enhance Medication Monitoring
Tuesday, April 24, 2012
10:30 a.m. – 12:00 p.m.

Jeffrey D. Baxter, MD, Department of Family Medicine and Community Health, University of Massachusetts Medical School, Shrewsbury, MA

Lisa M. Blanchard, MA, Spectrum Health Systems, Worcester, MA

Monitoring for the misuse of prescription medications with abuse potential is a significant challenge for opioid treatment programs.

Prescription monitoring programs provide an invaluable resource for enhancing medication monitoring. This workshop will explore the structure of prescription drug monitoring programs and how they vary across states; demonstrate the capabilities and discuss the limitations of the Massachusetts online prescription drug monitoring program; examine how prescription monitoring programs can be utilized at different stages of treatment; and will discuss how the introduction of the online prescription monitoring program in 2010 has enhanced screening and monitoring of patients through case study examples.

D1 Therapeutic Partnerships: The Most Important Evidence-Based Practice
Tuesday, April 24, 2012
1:30 p.m. – 3:00 p.m.

Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT

Research indicates that the quality of the therapeutic relationship has a greater effect on patient retention and outcomes than the specific counseling approach used. This workshop will focus on the essential, fundamental counseling skill of forming and maintaining the therapeutic relationship. The presenter will provide an overview of the factors that can impact the therapeutic relationship and the unique challenges involved in enhancing the therapeutic alliance with medication assisted patients within the clinical setting. A key area of focus will be counselor expectancy as a therapeutic factor. Boundary issues specific to the counselor in recovery will also be explored.

D2 Improving Efficiency and Cost through Patient-Directed Recovery-Oriented Care
Tuesday, April 24, 2012
1:30 p.m. – 3:00 p.m.

Peter Coleman, MS, NYC Health and Hospitals Corporation, New York, NY

Michael Norman Haynes, BA, NYC Health and Hospitals Corporation, New York, NY

Alicia Bartz, MA, NYC Health and Hospitals Corporation, New York, NY

Applying tools from the NIATx change process, the New York City Health and Hospitals Corporation (HHC) transitioned their treatment programs to a chronic care model. This effort resulted in improved access to services, enhanced patient care and support for long term recovery, efficient service delivery, and reduced costs. This workshop will review the basic principles of recovery; examine NIATx change tools; and explain how HHC integrated and operationalized these principles through integrated, multi-disciplinary customizable forms that include mandated data reporting elements, utilize the language of recovery, and facilitate the transfer of patients between programs. Easy, replicable examples will be provided to attendees.

D3 Emergency Management & Planning in OTPs
Tuesday, April 24, 2012
1:30 p.m. – 3:00 p.m.

Megan Marx, MPA, The Joint Commission, Oakbrook Terrace, IL

Deborah Powers, BS, Consultant, Madison, WI

Richard Weisskopf, BS, Illinois Department of Alcoholism and Substance Abuse, Chicago, IL

Developing an Emergency Management Plan is imperative for the well-being of OTP patients and staff. This workshop will focus on the impact of all types of emergencies on program operations and will identify critical elements of an effective emergency management plan including emergency mitigation, preparedness, response and recovery. The importance of developing community collaborations to respond to emergencies will also be addressed. Attendees will participate in small group discussions addressing critical communication strategies during an emergency, and how to ensure that patients and staff are notified of emergency procedures and access to care during a crisis.

D4 Electronic Information System Implementation at an Opioid Treatment Program
Tuesday, April 24, 2012    1:30 p.m. – 3:00 p.m.

Lawrence S. Brown, Jr., MD, Addiction Research and Treatment Corporation, Brooklyn, NY

Melissa Lin, MS, Addiction Research and Treatment Corporation, Brooklyn NY

Steven Kritz, MD, Addiction Research and Treatment Corporation, Brooklyn, NY

There is considerable discussion about ways to achieve desirable healthcare outcomes cost-effectively. Use of an electronic health information system has been the focus of many of these discussions, though generally not in substance abuse treatment settings. The Addiction Research and Treatment Corporation received a NIDA R01 funding grant to study the implementation of an electronic health information system at our methadone maintenance clinics. This workshop will focus on the roadblocks and challenges to implementation, the findings from the five domains examined by the research study, and areas where we have exploited system capabilities to positively impact patient care.

D5 The Overdose Prevention Toolkit for Opioid Treatment Programs
Tuesday, April 24, 2012    1:30 p.m. – 3:00 p.m.

LT Brandon Johnson, MBA, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

Fred Brason, II, Project Lazurus, North Wilkesboro, NC

Melinda Campopiano, MD, Western Psychiatric Institute and Clinic, Pittsburg, PA

This session will review the need for overdose prevention programs within the treatment community. Opiate treatment programs and providers are in a unique position to prevent overdose because of their interface with individuals combating opiate addiction and the inherent risk of overdose during medication induction. Overdose prevention within Opioid Treatment Programs may have important implications for reducing overdose-related morbidity and mortality.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).

E1 Recovery Partnerships: Developing and Integrating Peer Mentoring within MAT
Wednesday,  April 25, 2012
8:00 a.m. – 9:30 a.m.

Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT

Kurt Kemmling, CMA, CT Chapter National Alliance Methadone Advocates, Berlin, CT

This workshop will focus on the development, implementation, and integration of peer mentoring services within a methadone treatment program with a specific focus on strengthening the therapeutic alliance between the patient and the program. Potential benefits relating to patient outcomes and staff utilization management will be discussed. Short video clips of mentoring sessions will be presented followed by an interactive case discussion between the Peer Mentor and the workshop participants. The presenters will also focus on providing information that the workshop participants will need to replicate all or part of the initiative at their own programs.

E2 Integrating Evidence-Based Therapies for Co-Occurring Disorders

Wednesday,  April 25, 2012
8:00 a.m. – 9:30 a.m.

Mark McGovern, PhD, Dartmouth Medical School, Lebanon, NH

Paul McLaughlin, MA, Hartford Dispensary, Manchester, CT

Aliza Castro, LCSW, Hartford Dispensary, Hartford, CT

This workshop describes an integrated combined therapy (ICT) for co-occurring substance use and psychiatric disorders. The results of a randomized controlled trial comparing ICT to enhanced dual diagnosis services in a community methadone clinic are presented. ICT was delivered by counselors employed by the methadone program with high school to master’s level education. The enhanced dual diagnosis services were provided by experienced doctoral and master’s level clinicians. The findings from the randomized clinical trial are discussed from several vantage points: research, clinical, administrative, training and clinical supervision. Overall, ICT appears effective in reducing psychiatric and substance use severity.

E3 Methadone from Las Vegas & Tel Aviv to Macao, from Minneapolis to Vietnam

Wednesday,  April 25, 2012
8:00 a.m. – 9:30 a.m.

Einat Peles, PhD, Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse, Treatment & Research, Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel-Aviv, Israel

Hon Wai Wilson, BA, Division for Treatment and Rehabilitation of Drug Dependence, Social Welfare Bureau, Government of Macao Special Administrative Region, People’s Republic of China

Gavin Bart, MD, Division of Addiction Medicine, Hennepin County Medical Center, Minneapolis, MN

Opioid dependent individuals, their families, and communities throughout the world are benefiting from the development, expansion, and implementation of Methadone Maintenance Treatment (MMT). The similarity and differences with respect to guidelines and regulations, patient characteristics and outcomes will be described for: two “Adelson” clinics (Tel-Aviv, Israel and Las Vegas, Nevada); the first MMT program in Macao, founded in collaboration with the “Adelson” clinics; and MMT programs established in Vietnam, and a methadone clinic in Minneapolis, Minnesota that serves a large population of Southeast Asians.

E4 Delivering Successful MAT Services to Persons with Chronic Pain

Wednesday,  April 25, 2012
8:00 a.m. – 9:30 a.m.

Holly Hills, PhD, University of South Florida, Tampa, FL

Tara Richards, PhD(c), University of South Florida, Tampa, FL

Andre Benson, MD, Operation PAR, Port Richey, FL

One of the most common co-morbidities seen in individuals with opioid dependence is chronic pain. This workshop will review the literature related to the intersection between pain experience and opioid dependence. Presenters will examine findings from recently analyzed administrative data for persons in MAT care. Results describe the percentage of individuals whose opioid dependence was initiated after being prescribed pain medication following an accident, injury, or illness. Frequently documented co-occurring physical health diagnoses were also examined. Clinical challenges, opportunities associated with addressing chronic pain issues while treating opioid dependence, and clinical case examples will also be provided and discussed.

E5 Mindfulness Based Stress Reduction: A Means for Reducing Substance Use

Wednesday,  April 25, 2012
8:00 a.m. – 9:30 a.m.

Robert Sterling, PhD, Thomas Jefferson University, Philadelphia, PA

Stephen Weinstein, PhD, Thomas Jefferson University, Philadelphia, PA

Kate Vandergrift, MA, Thomas Jefferson University, Philadelphia, PA

Benzodiazepine use represents one of the most vexing problems confronting medication assisted treatment (MAT) providers with estimates indicating that anywhere from 30 to 70% of individuals in MAT will abuse benzodiazepines at some point. The purpose of this workshop is a demonstration of how the MAT programs of Thomas Jefferson University have implemented/integrated a mindfulness based stress reduction (MBSR) intervention into the treatment and recovery process. Close attention will be paid to MBSR’s efficacy with pregnant opiate addicted women. Preliminary outcome data will be presented. Means for training staff and implementing MBSR into the environment of care will be addressed.

9:45 a.m.–11:15 a.m.
F1 New Issues in the Diagnosis and Treatment of HCV

Wednesday, April 25, 2012
9:45 a.m. – 11:15 a.m.

Moderator: Richard A Denisco, MD, Services Research Branch, DESPR, NIDA, Rockville, MD

Presenters:
Uriel R. Felsen, MD, Albert Einstein College of Medicine/ Montefiore Medical Center, New York, NY

Jeanette M. Tetrault, MD, Yale University School of Medicine, New Haven, CT

Brian Pearlman, MD, Atlanta Medical Center, Atlanta, GA

Over 5 million people are chronically infected with viral hepatitis in the United States, with 2.7 to 3.9 million of those infected with hepatitis C virus (HCV). Over the last two decades, significant advances have been made in the diagnosis, treatment and adjuvant treatment of HCV. This year in fact, two medications have received FDA approval for HCV treatment that have improved HCV clearance or remission by over 25%. This combination of advances for HCV care make this an ideal time to update clinicians on improvements and coverage available to their patients.

F2 Medication Assisted Treatment Implementation in Community Correctional Environments (MATICCE): Preliminary Findings

Wednesday, April 25, 2012
9:45 a.m. – 11:15 a.m.

Kevin Knight, PhD, Texas Christian University, Fort Worth, TX

Lori Ducharme, PhD, Division of Epidemiology, Services & Prevention Research, National Institute on Drug Abuse, Bethesda, MD

Peter Friedman, MD, Rhode Island Hospital/Providence VAMC, Providence, RI

CJDATS II is a NIDA-funded five-year project that provides a platform for conducting implementation research in criminal justice settings. The MATICCE study engages correctional systems and community-based treatment providers in an implementation intervention that emphasizes staff training on the value of medication assisted treatment, and strategic planning to improve interorganizational linkages. These staff- and organizational-level interventions are expected to benefit offenders as measured by referral rates, treatment receipt, drug use outcomes, and recidivism. The implementation strategies provide a model for broader uptake of MAT, and for balancing public health and safety priorities in resource constrained systems. This panel provides summaries of preliminary findings.

F3 Shaping Our Future: Updates and Opportunities for the Addiction Care Field

Wednesday, April 25, 2012
9:45 a.m. – 11:15 a.m.

Paul Samuels, JD, Legal Action Center, New York, NY

Gabrielle de la Gueronniere, JD, Legal Action Center, Washington, DC

Dan Belnap, MA, Legal Action Center, Washington, DC

The health care system in this country is currently in a period of tremendous change. Just over a year and a half remains before the major provisions of the Affordable Care Act take effect. These changes have significant implications for the treatment delivery system, and increased coverage for critical drug and alcohol-related services means more people in need of treatment will be able to access it. This workshop will discuss current and future federal developments related to addiction treatment, the future of medication assisted treatment, delivery system reforms, and opportunities available for improving federal policy moving forward.

F4 Comprehensive Treatment of the Pregnant Substance User
Wednesday, April 25, 2012
9:45 a.m. – 11:15 a.m.

Van L. King, MD, Johns Hopkins Bayview Medical Center, Baltimore, MD

Neeraj Gandotra, MD, Johns Hopkins Bayview Medical Center, Baltimore, MD

Treatment of substance dependence is often challenging, and this challenge is even greater when complicated by pregnancy. Workshop leaders will describe the Center for Addiction and Pregnancy adaptive stepped care substance abuse treatment model, and how this model can be used to address substance use problems. Additional discussions will include: patient demographics, rates of specific drug use and psychiatric co-occurring disorders; medication management; collaborations with hospital services and community-based residential treatment services; research findings detailing the risks and long-term adverse outcomes of in-utero exposure to drugs and/ or alcohol; and barriers to care that interfere with treatment for pregnant women.

F5 Engaging Veterans and Families across the Lifespan
Wednesday, April 25, 2012
9:45 a.m. – 11:15 a.m.

Kellie Rollins, PsyD, San Francisco VA Medical Center, San Francisco, CA

John Straznickas, MD, San Francisco VA Medical Center, San Francisco, CA

Susan Storti, PhD, Behavioral Health Consultant, Cranston, RI

To date, over 1.8 million veterans have been deployed to the current conflicts. There are over 23 million living veterans. The majority are seeking treatment outside of VA settings. This workshop will enhance provider’s skills in engaging veterans in care.

The presenters will describe military culture and its importance in treating veterans; discuss the specific challenges military members, veterans, and their families endure throughout the deployment cycle; and identify effective treatment practices that address the unique challenges of engaging younger veterans.